Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Trial details

Who runs it

Amgen

Trial code

NCT07684144EU 2025-524788-19-00

Record updated

5 October 2026

Original description

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).Read full original descriptionShow less

A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants With Obesity or Overweight With Type 2 Diabetes Mellitus

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

Inclusion: Signed informed consent form (ICF) indicating compliance with the requirements and restrictions listed in the ICF and this protocol; Participants completing Study 20210184 must meet the following criteria:; Completed the Week 72 visit in Study 20210184; Did not permanently discontinue the investigational product in the parent trial (20210184); Randomized within 7 days of week 72 visit in the parent trial; Participants must use protocol-specified contraception during treatment and for 16 weeks after the last dose of trial intervention.

Exclusion: Planned (during the trial) surgical, endoscopic, or device-based treatment for obesity; Any malignancy diagnosed during the parent trial, except for the following treated with curative intent:; Nonmelanoma skin cancers; Breast ductal carcinoma in situ; Cervical carcinoma in situ; Prostate cancer in situ; Major surgical procedures planned during the trial; Participants with minor surgical procedures (not requiring general anesthesia or deep sedation) planned during the trial may be eligible at the discretion of the investigator; History of ischemic optic neuropathy; Newly identified (during the parent trial) multiple endocrine neoplasia syndrome type 2, or family history (first-degree relative[s]) history of medullary thyroid carcinoma (MTC); History or evidence of any other clinically significant disorder, condition, disease (including, but not limited to known drug or alcohol abuse, eating disorders, and conditions identified during the parent trial) that, in the opinion of the investigator, would pose a risk to participant safety; Body mass index (BMI) ≤ 18.5 kilograms per meter square (kg/m\^2); Participant has known sensitivity to any of the products or components to be administered during dosing; Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at the Week 72 visit from the parent trial (20210184) before randomization; Any suicidal ideation (category 4 or 5) or any suicidal behavior on the Columbia-Suicide Severity Rating Scale (C-SSRS), Since Last Visit version, at the Week 72 visit from the parent trial before randomization; Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator; Currently pregnant (confirmed with positive pregnancy test) or breastfeeding or planning to become pregnant or breastfeed while on trial until an additional 16 weeks after the last dose of trial intervention; Investigative site personnel directly affiliated with the trial and/or their immediate family (ie, spouse, parent, child, or sibling, whether biological or legally adopted).

ClinicalTrials.gov NCT07684144 · EU CTIS 2025-524788-19-00